Project Grant HT94252310956
Award Date
9/1/23
Completion Date
8/31/27
Dollars Obligated
$509K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
2323 Riverside Dr., Ottawa, ON K1H 1A1, Canada
Similar Awards
This $439,912 federal Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports research by the Provincial Health Services Authority, operating as BC Cancer, a major Canadian healthcare organization specializing in cancer research, treatment, and prevention. The grant aims to "HARNESSING THE IMMUNE RESPONSE IN EXCEPTIONALLY LONG-TERM SURVIVORS TO DEVELOP NOVEL THERAPEUTICS", leveraging BC Cancer's expertise...
The federal Project Grant award of $438,500.00 from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) will support research conducted by the Provincial Health Services Authority in Canada, operating under the name BC Cancer, to decode and target genomic instability in pediatric osteosarcoma. The project, with a period of performance from September 30, 2023 to September 29, 2025, aims to develop innovative solutions for cancer treatment,...
The U.S. Defense Health Agency awarded a $907,170 Project Grant to the Provincial Health Services Authority (operating as BC Cancer) in Canada. This grant, provided under the Department of Defense's Military Medical Research and Development program (CFDA 12.420), supports research on therapeutic targeting of genomic instability in triple-negative breast cancer. The 3-year project, running from September 2023 to September 2026, aims to advance the understanding and treatment of this aggressive...
The University of British Columbia (UBC) received a $507,035 Project Grant award from the Defense Health Agency under the Military Medical Research and Development Program (CFDA 12.420). The grant, awarded on September 1, 2023, will fund research for "The Ovarian Cancer Observatory: Prevention, Impact, and Learning from Opportunistic Salpingectomy" over a 4-year period through August 31, 2027. As the prime grantee, UBC will leverage its expertise in medical research and data analysis...
The U.S. Defense Health Agency awarded a $109,895 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to the Provincial Health Services Authority (operating as BC Cancer) in Canada. The grant is for the purpose of "DEVELOPING FIRST-IN-KIND PRECLINICAL MODELS OF PRIMARY TESTICULAR LYMPHOMA" over a 2-year period from September 1, 2024 to August 31, 2026. As a prominent Canadian healthcare organization specializing in cancer research, treatment, and...
The federal Project Grant award from the Defense Health Agency, under the Military Medical Research and Development program (CFDA 12.420), provides $807,400.00 to the Provincial Health Services Authority (BC Cancer) in Canada. The grant, awarded on May 1, 2024, supports a research project titled "DECODING HOW DISTINCT MECHANISMS OF GENOMIC INSTABILITY FOUND IN TNBC PATIENTS PROGRAM THE TISSUE MICROENVIRONMENT AND THERAPY RESPONSE AT METASTATIC SITES." This project aims to investigate...
The Department of the Army Medical Command awarded a $990,000 project grant to the Provincial Health Services Authority in Canada to support research on mechanisms and therapeutic strategies for overcoming MNA-mediated immune suppression in ovarian cancer. The grant was awarded under the Military Medical Research and Development program (CFDA 12.420), which aims to transform health care for service members and the public through innovative biomedical research solutions for battlefield...
This federal Project Grant award of $1,477,615.00 from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports advanced biomedical research focused on comparative transcriptomic and proteomic profiling of full-length androgen receptor (AR) and AR-V7 splice variant condensates in prostate cancer. The funding will enable The University of British Columbia, a prominent Canadian research university, to leverage its world-class facilities and...
This Project Grant award for $1,126,685 from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) supports translatome profiling research conducted by the University of British Columbia (UBC) to identify biomarkers and therapeutic targets for prostate cancer. The project aims to leverage UBC's expertise in biomedical research and advanced analytical capabilities to advance the understanding and treatment of prostate cancer, which is an...
The U.S. Defense Health Agency awarded a $399,816 Project Grant to The University of British Columbia (UBC) for the project "ENGINEERING NEXT-GENERATION SELF-AMPLIFYING RNA THERAPEUTICS ENCODING BISPECIFIC T-CELL ENGAGER (BITE) ANTIBODIES FOR TREATMENT OF OVARIAN CANCER." The grant, funded under the Military Medical Research and Development program (CFDA 12.420), supports UBC's research to develop innovative self-amplifying RNA-based therapies encoding bispecific T-cell engager...